

Journal of Visualized Experiments

Ex vivo-infection of human lymphoid tissue and female genital mucosa with human immunodeficiency virus 1 and histoculture.

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE57013R2
Full Title:	Ex vivo-infection of human lymphoid tissue and female genital mucosa with human immunodeficiency virus 1 and histoculture.
Keywords:	HIV; human immunodeficiency virus 1; histoculture; tissue explants; ex vivo; infection; pathogenesis; lymphoid tissue; tonsils; cervical mucosa; female reproductive tract
Corresponding Author:	Andrea Introini Karolinska Institutet Stockholm, Stockholm SWEDEN
Corresponding Author's Institution:	Karolinska Institutet
Corresponding Author E-Mail:	andrea.introini@ki.se
First Author:	Andrea Introini
Other Authors:	Christophe Vanpouille Kristina Broliden Leonid Margolis
Author Comments:	
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

TITLE:

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture

AUTHORS & AFFILIATIONS:

Andrea Introvini^{1,2}, Christophe Vanpouille², Kristina Broliden¹, Leonid Margolis²

¹Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

²Section of Intercellular Interactions, Eunice Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda MD, USA

CORRESPONDING AUTHOR:

Andrea Introvini

Email Address: andrea.introvini@ki.se

EMAIL ADDRESSES OF CO-AUTHORS:

Christophe Vanpouille (vanpouic@mail.nih.gov)

Kristina Broliden (kristina.broliden@ki.se)

Leonid Margolis (margolil@mail.nih.gov)

KEYWORDS:

HIV, human immunodeficiency virus 1, histoculture, tissue explants, *ex vivo*, infection, pathogenesis, lymphoid tissue, tonsils, cervical mucosa, female reproductive tract

SUMMARY:

Infection of human tissues with human immunodeficiency virus (HIV) *ex vivo* provides a valuable 3D model of virus pathogenesis. Here, we describe a protocol to process and infect tissue specimens from human tonsils and female genital mucosae with HIV-1 and maintain them in culture at the liquid-air interface.

ABSTRACT:

Histocultures allow studying intercellular interactions within human tissues, and they can be employed to model host-pathogen interactions under controlled laboratory conditions. *Ex vivo* infection of human tissues with human immunodeficiency virus (HIV), among other viruses, has been successfully used to investigate early disease pathogenesis, as well as a platform to test the efficacy and toxicity of antiviral drugs. In the present protocol, we explain how to process and infect with HIV-1 tissue explants from human tonsils and cervical mucosae, and maintain them in culture on top of gelatin sponges at the liquid-air interface for about two weeks. This non-polarized culture setting maximizes access to nutrients in culture medium and oxygen, although progressive loss of tissue integrity and functional architectures remains its main limitation. This method allows monitoring HIV-1 replication and pathogenesis using several techniques, including immunoassays, qPCR, and flow cytometry. Of importance, the physiologic variability between tissue donors, as well as between explants from different areas of the same specimen, may significantly affect experimental results. To ensure result reproducibility, it is critical to use an

adequate number of explants, technical replicates, and donor-matched control conditions to normalize the results of the experimental treatments when compiling data from multiple experiments (*i.e.*, conducted using tissue from different donors) for statistical analysis.

INTRODUCTION:

Monotypic bi-dimensional cell cultures, here referred to as conventional, do not account for the spatial and functional communication between the large variety of cell types that compose tissues and organs. This aspect is of paramount importance for experimental models of disease, as interference with homeostatic intercellular interactions is the driving factor of all pathologies. Tissue explants offer major advantages for modeling health and disease in humans because they retain the cytoarchitecture and many important functional aspects of organs as they are *in vivo*, although for a limited amount of time¹. For example, upon *ex vivo* challenge with recall antigens, such as diphtheria toxoid or tetanus toxoid, tonsillar tissue responds with a vigorous production of antigen-specific antibodies². Like any other *ex vivo* model, histoculture has its own limitations: inter-donor variability, tissue polarization, limited tissue survival, and difficulty in monitoring cells beyond the depth of confocal microscopy¹. Nevertheless, human tissue explants remain a model of choice to study homeostatic and pathogenic immunological processes in humans, including host-pathogen interactions and potential therapeutic interventions³.

The critical events of HIV-1 pathogenesis take place in tissues. Infection of the genital mucosa accounts for the majority of all HIV-1 transmission events worldwide⁴. Lymphoid tissue is the major site of virus replication during acute infection and harbors a significant pool of latently-infected cells⁵, and their persistence represents the main obstacle to achieve a cure⁶. The culture and *ex vivo* challenge of human lymphoid and mucosal tissues provide some advantages over conventional systems based on isolated cells for the study of HIV-1. For instance, tissue-resident cells can support HIV-1 infection in the absence of exogenous activation, as opposed to peripheral blood mononuclear cells¹. The use of lymphoid tissue explants has allowed a better understanding of some key mechanisms underlying CD4 T cell depletion, *i.e.*, the bystander effect⁷, which is the hallmark of acute infection. The preservation of structures like B cell follicles in lymphoid tissue⁸ and the epithelium in female genital mucosa explants⁹ offers the unique opportunity to integrate spatial and functional features of HIV-1 infection at these sites. Finally, histocultures were successfully used to model and study HIV-1 and herpesvirus co-infection^{10,11}, as well as for preclinical testing of antiretrovirals and multitarget microbicides¹²⁻¹⁵.

Here, we describe a detailed protocol for the culture of human tissue explants obtained from tonsils and mucosal tissue from the lower female genital tract (cervix), covering tissue dissection to explant challenge with HIV-1 in a non-polarized way. The culture of tissue explants at the liquid-air interface, using gelatin sponges as a support, maximizes exposure to air oxygen while providing access to culture medium nutrients through the sponge capillaries, thus delaying their natural decay. The most immediate way of evaluating HIV-1 replication in our system is to measure the amount of virus released in the explant culture medium over time by immunoassay or qPCR. HIV-1 infection and pathogenesis (*e.g.*, CD4 T cell depletion) can also be evaluated in tissue explants by bulk RNA/DNA extraction and qPCR, *in situ* staining, or single cell-analysis upon tissue digestion by flow cytometry.

PROTOCOL

The protocol for collection of human tissues may require ethical approval by the local competent authorities. In case of indicated surgeries such as tonsillectomy and hysterectomy, the specimens are not collected specifically for research purpose and the study is not considered human subjects research (National Institutes of Health. Research on Human Subjects. <https://humansubjects.nih.gov/walkthrough-investigator#tabpanel11>). However, obtaining tissue donors' personal and medical data (*e.g.*, sex, age, current drug use, history of infections, *etc.*) that may help interpret experimental results, poses concerns about informed consent and privacy that must be addressed in the protocol for tissue collection.

Caution: The entire procedure should be carried out in a biological safety cabinet. All human specimens, including those from 'healthy' individuals, may harbor infectious agents. The operator should receive training to work with blood-borne pathogens to safely handle tissue specimens, even if experiments do not involve the use of HIV. A risk assessment of the procedure of tissue dissection and infection with HIV should be carried out by trained staff to ensure the safety of the operator and coworkers. The use of infectious HIV requires dedicated biosafety level 2 or 3 environments depending on the country and institute-specific regulations on hazardous biologicals and blood-borne pathogens.

1. Preparation of Gelatin Sponges

Note: Although it is not strictly necessary to prepare gelatin sponges before tissue dissection, it is more convenient to follow the order outlined here, especially when handling a large amount of tissue and/or from many donors.

1.1. Prepare culture medium (CM) and supplement it with antibiotic solution (Ticarcillin-clavulanate mix) before use to make CMT (**Table of Materials**). Discard any leftover antibiotic solution.

Note: Ticarcillin and clavulanate in CMT are poorly stable. If needed, re-supplement CMT with antibiotic solution after about 24 h from preparation. It is not required to add antibiotic solution to explant medium every 24 h during culture.

1.2. Fill a 100 mm x 20 mm Petri dish with about 20–30 mL of CMT.

Note: This setting is optimal to prepare enough gelatin sponges for two 6-well plates or one 12-well plate at the time. If many plates are required, use a wider Petri dish and larger CMT volume to speed up the preparation.

1.3. Transfer the gelatin sponge(s) into the Petri dish using sterile forceps. Wet the sponges on both sides and allow the sponges to soak up medium for 1 min. Press the sponges against the bottom of the Petri dish for about 2 min using a sterile spatula.

Note: This step is of crucial importance because the presence of air bubbles in the sponge will block the capillaries through which culture medium nutrients reach the tissue. Gelatin sponges are extremely brittle when dehydrated. Gently push down on the sponge with the spatula, especially at the beginning, to avoid breaking the sponge.

1.4. Use sterile scissors to cut the rehydrated gelatin sponges into pieces of equal size of about 1 cm². Transfer 1 sponge piece using forceps into each well of a culture plate. Add 3–4 mL of CMT into each well of a 6-well plate (tonsils) and 1 mL per well into a 12-well plate (cervix). Place the plates in the incubator, set at 37 °C, 5% CO₂, ≥ 90% humidity, until the tissue explants are ready to be loaded on the sponges.

Note: The volume of CMT to add into the plate should be adjusted to the thickness of the sponge to keep the explants at the liquid-air interface.

2. Dissection of Human Tonsillar Tissue

Note: Tonsils should be processed as soon as possible after surgery, ideally the same day of surgery. Alternatively, specimens can be left overnight submerged in CMT at 4 °C.

2.1. Allow the CM enough time to reach room temperature (RT) or put it in a water bath pre-warmed at 37 °C. Supplement the CM with antibiotic solution (CMT) before use. Discard any antibiotic solution left over. Pour 70% ethanol solution into a clean container to soak forceps and scalpel whenever needed during the dissection procedure. Clean the tools and change the scalpel blade between dissections of specimens from different donors.

2.2. Transfer the tonsils from the transportation container into a 100 mm-Petri dish containing 10–20 mL of CMT using sterile forceps.

Note: Specimens with widespread areas of cauterized, bloody, or necrotic tissue should be discarded.

2.3. Use the lid of the Petri dish as a cutting surface to dissect tissue. Holding the tissue gently with forceps, cut each tonsil into several big pieces using sterile scalpel and blade.

Caution: Handling sharp tools to dissect human specimens increases the risk of injury and contamination. The operator should consider wearing metal, mesh, cut-resistant gloves as additional protection.

2.4. Remove cauterized, bloody, and fibroid tissue, and any parts containing tonsilloliths (calcified material) and/or with green-brownish color using forceps and scalpel.

Note: While working on one piece of tissue, it is important to keep the rest of the tissue submerged in medium to avoid tissue desiccation.

2.5. Cut each tissue piece into slices of about 2 mm in thickness. Remove any unwanted part as in the previous step. Cut the tissue slices into 2 mm-thick strips. Cut the tissue strips into 2 mm-thick blocks. This should result in tissue explants of roughly 8 mm³.

2.6. Transfer the explants into a new 100 mm-Petri dish containing 10–20 mL of CMT to avoid tissue desiccation while proceeding with the dissection. At the end of dissection, swirl the plate to randomize the explant distribution. Place 9 tissue explants on top of each gelatin sponge in a 6-well plate using forceps, allowing space between them. Return the plates to the incubator.

Note: Typically, explants are cultured overnight and inoculation of cultures with HIV-1 is performed the next day. This is to make sure that no bacterial or fungal contamination develops in the culture. In addition, cells tend to egress tonsillar tissue explants after dissection. This process is largely completed within the first 24 h of culture¹.

2.7. Dispose of all biological waste in apposite containers according to the institute's regulations on handling hazardous biologicals and the specific risk assessment.

3. Infection of Tonsillar Tissue Explants with HIV-1

Note: To reduce result variability between independent experiments, the same virus preparation should be used for an entire study. Virus can be propagated in exogenously activated peripheral blood mononuclear cells and then the culture supernatant can be aliquoted for storage at -80 °C to avoid repeated freezing and thawing (**Table of Materials**).

3.1. Put the CM in a water bath pre-warmed at 37 °C. Supplement the CM with antibiotic solution (CMT) before use. Discard any leftover antibiotic solution.

3.2. Aspirate the medium in the 6-well plate(s) with a pipette and discard it in a container with disinfectant solution. Tilt the plate and gently push the gelatin sponges to the upper part of the well to allow the medium to gather at the bottom, and aspirate and discard it. Add 3–4 mL of CMT to each well.

3.3. Thaw the HIV-1 virus preparation in the water bath at 37 °C. If necessary, dilute the virus stock with CM (**Table 1**).

Note: The virus stock should be diluted so that the selected inoculum is contained in a volume of 5–8 µL (**Table 1**). For an efficient infection, it is critical to use the minimum time required between thawing the HIV-1 preparation and infecting tissue explants.

3.4. Pipette the virus inoculum directly on top of each of the 9 explants on a gelatin sponge. Return the plate(s) to the incubator as soon as the infection is completed. Discard any residual virus preparation. Continue to Section 5.

Note: To accurately deliver the virus inoculum the operator should consider using a reverse

pipetting technique and changing the tip for every well. This involves pushing the pipette piston down to the purge position (the second stop) to draw the virus inoculum up, and pushing to the first stop to deliver the inoculum, which helps minimizing bubble formation and the error associated with repeated sampling of small volumes, *i.e.*, 5–8 μL .

4. Dissection and Infection of Uterine Cervical Mucosa

Note: For optimal results, explants of cervical mucosae should be processed and infected as soon as possible after surgery, ideally the same day of surgery. Alternatively, specimens can be stored submerged in CMT at 4 °C overnight, and infected immediately after dissection.

4.1. Allow the CM enough time to reach RT or put it in a water bath pre-warmed at 37 °C. Supplement the CM with antibiotic solution (CMT) before use. Discard any leftover antibiotic solution. Pour 70% ethanol solution into a clean container to soak the forceps and scalpel whenever needed during the dissection procedure. Clean the tools and change the scalpel blade between dissections of specimens from multiple donors.

4.2. Using sterile forceps, transfer the sample from the transportation container into a 100 mm-Petri dish containing 10–20 mL of CMT.

4.3. Use the lid of the Petri dish as a cutting surface to dissect the tissue. Holding the tissue gently with forceps, separate the mucosa of the ectocervix and/or endocervix from the underneath stromal and muscular tissue (submucosa) with a scalpel and blade to obtain strips of mucosa.

Note: While working on one piece of tissue, it is important to keep the rest of the tissue submerged in medium to avoid tissue desiccation.

4.4. Cut the mucosa into 2 mm-wide strips, remove and discard as much submucosa as possible, leaving only a 2 mm-thick layer of tissue. Cut the strips into 2 mm-thick blocks. This should result in tissue explants of roughly 8 mm³.

Caution: Handling sharp tools to dissect human specimens increases the risk of injury and contamination. The operator should consider wearing metal, mesh, cut-resistant gloves as additional protection.

4.5. Transfer tissue explants into a new 100 mm-Petri dish containing 10–20 mL of CMT to avoid tissue desiccation while proceeding with the dissection. At the end of dissection, swirl the plate to randomize the explant distribution.

4.6. With sterile forceps, transfer the explants into sterile 1.5-mL conical tube(s) (maximum 16 explants per tube). Remove any medium in the tube using a pipette.

4.7. Thaw the HIV-1 preparation in a water bath at 37 °C. If necessary, dilute the virus stock with CM. Transfer the virus into the tube(s) containing the explants. Discard any residual virus

preparation.

Note: The virus stock should be diluted so that the selected inoculum is contained in a volume of minimum 0.5 mL (**Table 1**). To reduce result variability between independent experiments, the same virus preparation should be used for an entire study (**Table of Materials**).

4.8. Transfer the tubes into a thermo-shaker and incubate for 2 h at 37 °C rocking at 300 rpm. Gently invert the tubes a few times every 30–60 min.

Note: For an efficient infection, it is critical to use the minimum time required between thawing the HIV-1 preparation and transferring the tubes to 37 °C.

4.9. Fill a 6-well plate with 3–4 mL per well of sterile phosphate buffer saline (PBS). At the of the incubation with HIV-1, discard all virus preparation in the tube(s) into a container with disinfectant solution using a pipette. Transfer the explants into the 6-well plate containing PBS using forceps.

4.10. Allow the explants to rest in PBS for 1 min at RT, and then wash them by gently pipetting up-and-down the PBS into the well 2–3 times. Discard the PBS into a container with disinfectant solution using a pipette. Add 3–4 mL of new PBS to each well. Repeat two more times for a total of three washes. Discard the PBS just before transferring the explants to the sponges to avoid tissue desiccation.

Note: Explants of cervical mucosa, and in particular endocervix, release great amounts of mucus during infection. It is critical to wash and remove as much mucus as possible because unspecific retention on explants and subsequent release of virus into culture supernatant can mask virus replication.

4.11. Using forceps, transfer 5–8 explants on top of each gelatin sponge in a 12-well plate. Return the plate to the incubator.

4.12. Dispose of all biological waste in apposite containers according to the institute's regulations on handling hazardous biologicals and the specific risk assessment.

5. Histoculture

5.1. Change the CM every 3 days starting from the time of infection until day 12–15 post-infection. The CM and/or explants can be sampled at regular intervals throughout the culture time to assess HIV-1 replication, among other parameters.

5.2. Put the CM in a water bath pre-warmed at 37 °C.

Note: It is not required to supplement the CM with antibiotic solution at this stage.

5.3. Collect a sample of CM with a pipette and transfer it into sterile 1.5- or 2-mL screw cap tube(s) for storage at -80 °C.

Note: The CM from replicate wells are pooled at collection.

5.4. Harvest the tissue explants with sterile forceps, remove the excess medium on explants by placing them on a piece of paper (optional), and transfer explants into sterile 1.5- or 2-mL screw cap tube(s). Process or store the tissue samples as required by the experiment.

Note: For flow cytometry, explants are immediately digested with an enzymatic cocktail to obtain a single-cell suspension (for more details see references 1, 9, 16, and 17). For RNA extraction, explants are kept in a RNA stabilization solution at 4 °C overnight before storing them at -80 °C. For DNA extraction or *in situ* staining (cervix), explants can be snap-frozen in liquid nitrogen or dry ice/ethanol slurry and stored at -80 °C. Alternatively, tonsillar explants can be fixed by submersion in a solution of PBS and 4% paraformaldehyde for *in situ* staining.

5.5. Aspirate the residual CM in the well with a pipette and discard it into a container with disinfectant solution. Tilt the plate and gently push the gelatin sponges to the upper part of the well to allow the medium to gather at the bottom, and then aspirate and discard it.

5.6. Add 3–4 mL of CM to each well. Using sterile forceps, return any tissue explants that dropped into the medium to the gelatin sponge. Return the plate to the incubator.

5.7. At the end of culture, dispose of all biological waste in apposite containers according to the institute's regulations on handling hazardous biologicals and the specific risk assessment.

REPRESENTATIVE RESULTS:

Several techniques can be used to assess HIV-1 replication in tissue explants. Our standard read-out is to measure the amount of HIV-1 p24_{gag} released in CM over time with an immunoassay¹⁸.

Tissue explants from different donors, infected with the same inoculum of the same HIV-1 stock, may yield different amounts of virus (**Table 1**). This is due to several factors, such as the number and status of HIV-1 target cells and the presence of co-infecting pathogens in the tissue^{16,19}. In **Figure 1**, we provide an example of productive and abortive HIV-1 infection of cervical mucosa explants as defined by the amount of p24_{gag} released in CM compared to donor-matched explants treated with the antiretroviral drug lamivudine (3TC) that completely suppresses HIV-1 replication. Although this control appears superfluous for infection of tissue explants from the donor in A, it helps in discriminating abortive (B) from productive infection (C) in explants that yield low levels of HIV-1 replication.

The use of an antiretroviral drug as a control condition can be useful to study HIV-1 infection in tissues that harbor low numbers of target cells, like the cervical mucosa, and when using slow-replicating HIV-1 variants, such as some primary isolates. In addition, for tissues infected with such viruses, it is important to consider using more sensitive detection methods, for instance

qPCR.

FIGURE & TABLE LEGENDS:

Figure 1. HIV-1 replication in cervical mucosa explants from three different tissue donors. Cervical tissue explants were infected with the same inoculum of HIV-1_{BaL} by submersion in virus stock and cultured for 15 days in the presence or absence of the antiretroviral drug lamivudine (3TC) at the concentration of 10 μ M. Culture medium was sampled every 3 days and samples from replicate wells were pooled at collection for analysis of HIV-1 replication by HIV-1 p24_{gag} immunoassay.

Table 1. Reference values of HIV-1 inoculum for infection of tissue explants and virus production. The value of HIV-1 inoculum per individual tissue explant refers to virus stocks at the concentration of 50–70 ng/mL: a volume of 7 μ L of undiluted virus stock is used to infect each tonsillar explant on top of a gelatin sponge; a volume of 500 μ L of undiluted virus stock is used to infect 16 cervical explants by submersion in a 1.5 mL tube. Cervical explants are extensively washed in PBS before transferring them onto gelatin sponges. The value of HIV-1 production by tissue explants refers to the cumulative amount of p24_{gag} released by 8 explants in 1 mL (cervix), or 9 explants in 3–4 mL (tonsils) of culture medium (CM) sampled every 3 days over 12–15 days of culture. CM from replicate wells is pooled at collection for each time point before replacing it with fresh CM. The value of p24_{gag} concentration measured at day 3 was excluded from analysis because it partially accounts for virus absorption on explants and subsequent release into CM, *i.e.*, inoculum carry-over. Typically, the infection of cervical tissue with HIV-1_{LAI.04} does not lead to detectable HIV-1 replication in our experimental system¹⁶.

DISCUSSION:

The use of human tissue explants for the study of HIV-1 infection provides advantages over traditional bi-dimensional and monotypic experimental systems, such as primary cells or cell lines, due their superior ability to reproduce intercellular interactions and cellular functions (*e.g.*, cytokine production) as they are *in vivo*. Nevertheless, tonsillar and cervical tissue differ in many aspects including the number, and phenotypic and functional characteristics of HIV target cells^{1,16}. For the same reason, HIV-1 variants with different co-receptor tropism (*e.g.*, CCR5-tropic HIV-1_{BaL} vs. CXCR4-tropic HIV-1_{LAI.04}) perform differently both in tonsils and cervix (**Table 1**). The distribution of HIV coreceptors on target cells at the immune inductive and effector sites only partially accounts for local susceptibility to infection: CD4 T cells carrying CXCR4 are more abundant than CCR5-expressing cells in tonsillar tissue, thus explaining higher replication levels of HIV-1_{LAI.04} than HIV-1_{BaL}, but the receptors are equally represented in the cervical mucosa¹⁶. Nevertheless, we rarely detected productive virus replication in cervical tissue challenged with HIV-1_{LAI.04}, which is in line with the preferential transmission of individual HIV-1 CCR5-tropic variants observed *in vivo*²⁰. This suggests that the differentiation and activation status of HIV-1 target cells may ultimately determine their ability to support HIV-1 replication¹⁶.

Gelatin sponges are hemostatic devices obtained from purified porcine skin (collagen), which are designed to be completely absorbed by the human body after a few weeks. We recommend using products that show slow degradation rate in culture as they better suit the purpose of

maintaining tissue explants at the liquid-air interface for 2–3 weeks. We also recommend testing different batches of the same product to assess consistent performance in explant culture. Similarly, the type and lot of fetal bovine serum (FBS) can affect HIV-1 replication levels. We advise testing several lots of FBS for CM optimization and use the same lot of FBS for an entire study. We routinely test FBS on tissue explants from 10 donors and select the lot that gives the highest HIV-1 replication.

For most of the experiments, we pool explants from endocervix and ectocervix to maximize the number of experimental conditions. One may consider keeping them separated because of their different structural and immunologic features²¹. Also, endocervical explants release and continue to produce a great amount of mucus in culture that might interfere with downstream analysis. Seeing as the area covered by endocervix is much smaller than ectocervix, it is challenging to conduct HIV infection experiments exclusively on the endocervical mucosa using an adequate number of explants and technical replicates.

Performing HIV-1 infection by submersion of cervical explants maximizes the chances of obtaining a productive infection due to the lower number of CD4 T cells present in the mucosa compared with lymphoid tissue. For the same reason, the cervical tissue is more sensitive to overnight storage and yields higher HIV-1 replication when infected shortly after surgery and immediately after dissection. Although infection by submersion in virus stock can be performed also for tonsillar tissue to ensure uniform exposure of explants to the virus, this approach entails higher tissue manipulation and cell loss than infection of explants on gelatin sponges as described in the protocol.

Polarized systems of HIV-1 challenge and culture of mucosal tissues exist and are currently used in other laboratories^{3,22-25}. Although these systems are a valuable model of HIV-1 entry and penetration into the mucosa, their set up is generally more time-consuming and may require extensive tissue manipulation. Non-polarized models of mucosal transmission/pathogenesis still offer a valid platform to investigate the regulation of HIV-1 replication and the local pool of HIV-infected cells by endogenous and exogenous factors^{9,17,26}, including drugs¹²⁻¹⁵.

Inter-donor variability can represent a major issue for result reproducibility between independent experiments conducted using specimens from multiple donors. Variability in cellular composition may also affect areas within the same specimen, *i.e.*, intra-donor variability. To reduce variability and properly interpret results, it is critical to set up all conditions within one experiment using an adequate number of explants obtained from the same donor (donor-matched conditions). Results can be normalized to an internal control when compiling data from multiple experiments for statistical analysis. To reduce intra-donor variability, we recommend including at least 2 technical replicates for each experimental condition, for a total of 18 explants of tonsillar tissue (9/well), and 10–16 explants of cervical mucosa (5–8/well) (**Table 1**). The availability of medical records and the inclusion of additional analysis of patient material and/or experimental conditions, for instance to address the inflammatory status of a specimen, may significantly improve result interpretation (see reference 9 for an example).

ACKNOWLEDGMENTS:

This work was supported by grants from the Foundation Blanceflor Boncompagni Ludovisi nee Bildt (<http://blanceflor.se/>), the Foundation Swedish Physicians against AIDS (<http://www.aidsfond.se/>, ref. FOa2014-0006), and Fondazione Andrea e Libi Lorini (<http://fondazioneLorini.it/>) to Andrea Introini.

DISCLOSURES:

The authors have nothing to disclose.


REFERENCES:

1. Grivel, J.C., Margolis, L. Use of human tissue explants to study human infectious agents. *Nature protoc.* **4** (2), 256-269, doi: 10.1038/nprot.2008.245 (2009).
2. Glushakova, S., Grivel, J.C., Fitzgerald, W., Sylwester, A., Zimmerberg, J., Margolis, L.B. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. *Nat Med.* **4** (2), 346-349 (1998).
3. Dezzutti, C.S. Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success? *J Int AIDS Soc.* **18** (1), 20301, doi: 10.7448/IAS.18.1.20301 (2015).
4. UNAIDS, Global epidemic Update 2016. Available at: <http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016>
5. Lederman, M.M., Margolis, L. The lymph node in HIV pathogenesis. *Semin Immunol.* **20** (3), 187-95, doi: 10.1016/j.smim.2008.06.001 (2008).
6. Chun, T.W., Moir, S., Fauci, A.S. HIV reservoirs as obstacles and opportunities for an HIV cure. *Nat Immunol.* **16** (6), 584-9, doi: 10.1038/ni.3152 (2015).
7. Biancotto, A. et al. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. *Blood.* **111** (2), 699-704, doi: 10.1182/blood-2007-05-088435 (2008).
8. Van Laar, J.M. et al. Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells. *Am J Pathol.* **171** (3), 917-927, doi: 10.2353/ajpath.2007.070005 (2007).
9. Introini, A. et al. Seminal plasma induces inflammation and enhances HIV-1 replication in human cervical tissue explants. *PLoS Pathog.* **13** (5), e1006402, doi: 10.1371/journal.ppat.1006402 (2017).
10. Grivel, J.C. et al. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. *Nat Med.* **7** (11), 1232-5, doi: 10.1038/nm1101-1232 (2001).
11. Rollenhagen, C., Lathrop, M.J., Macura, S.L., Doncel, G.F., Asin, S.N. Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides. *Mucosal Immunol.* **7** (5), 1165-74, doi: 10.1038/mi.2014.3 (2014).
12. Lisco, A. et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. *Cell Host Microbe.* **4** (3), 260-270, doi: 10.1016/j.chom.2008.07.008 (2008).
13. Vanpouille, C. et al. A common anti-cytomegalovirus drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo. *AIDS.* **31** (11), 1519-1528, doi:

10.1097/QAD.0000000000001532 (2017).

14. Andrei, G. et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. *Cell Host Microbe*. **10** (4), 379-389, doi: 10.1016/j.chom.2011.08.015 (2011).
15. Greenhead, P., Hayes, P., Watts, P.S., Laing, K.G., Griffin, G.E., Shattock, R.J. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. *J Virol*. **74** (12), 5577-86 (2012).
16. Saba, E. et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. *Mucosal Immunol*. **3** (3), 280-290, doi: 10.1038/mi.2010.2 (2010).
17. Introini, A., Vanpouille, C., Lisco, A., Grivel, J.C., Margolis, L. Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. *PLoS Pathog*. **9** (2), e1003148, doi: 10.1371/journal.ppat.1003148 (2013).
18. Biancotto, A. et al. A highly sensitive and dynamic immunofluorescent cytometric bead assay for the detection of HIV-1 p24. *J Virol Methods*. **157** (1), 98-101, doi: 10.1016/j.jviromet.2008.11.013 (2009).
19. Lisco, A., Vanpouille, C., Margolis L. War and peace between microbes: HIV-1 interactions with coinfecting viruses. *Cell Host Microbe*. **6** (5), 403-408, doi: 10.1016/j.chom.2009.10.010 (2009).
20. Keele, B.F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A*. **105** (21), 7552-7, doi: 10.1073/pnas.0802203105 (2008).
21. Pudney, J., Quayle, A.J., Anderson, D.J. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. *Biol Reprod*. **73** (6), 1253-1263, doi: 10.1095/biolreprod.105.043133 (2005).
22. Ganor, Y. et al. Within 1h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. *Mucosal Immunol*. **3** (5), 506-22, doi: 10.1038/mi.2010.32 (2010).
23. Cavarelli, M., Foglieni, C., Rescigno, M., Scarlatti, G. R5 HIV-1 envelope attracts dendritic cells to cross the human intestinal epithelium and sample luminal virions via engagement of the CCR5. *EMBO Mol Med*. **5** (5), 776-94, doi: 10.1002/emmm.201202232 (2013).
24. Cummins, J.E. Jr. et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. *Antimicrob Agents Chemother*. **51** (5), 1770-9, doi: 10.1128/AAC.01129-06 (2007).
25. Abner, S.R. et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. *J Infect Dis*. **192** (9), 1545-56, doi: 10.1086/462424 (2005).
26. Saba, E. et al. Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. *Mucosal Immunol*. **6** (6), 1081-90, doi: 10.1038/mi.2013.2 (2013).

Figure 1



Tissue type	Virus	Inoculum per explant (pg of HIV-1 p24 _{gag})	No. of explants	Culture medium volume (mL)	No. of wells (technical replicates)	HIV-1 p24 _{gag} production (ng/mL)
Tonsillar	HIV-1 _{BaL}	350-500	9	3-4	2-3	1-10
	HIV-1 _{LAI.04}		9	3-4	2-3	1-100
Cervical	HIV-1 _{BaL}	1500-2000	8	1	2	1-5
	HIV-1 _{LAI.04}		8	1	2	undetectable

Name of Material/ Equipment	Company	Catalog Number
Gelfoam 12-7 mm Absorbable gelatin sponge	Pfizer	NDC: 0009-0315-08
SPONGOSTAN Standard 70 × 50 × 10 mm Absorbable haemostatic gelatin sponge	Ferrosan Medical Devices	MS0002
RPMI 1640 with phenol red and glutamine	ThermoFisher Scientific	21875034
Modified Eagle's medium (MEM) non-essential aminoacids (100x)	ThermoFisher Scientific	11140035
Sodium pyruvate, 100 mM (100x)	ThermoFisher Scientific	11360070
Gentamicin 50 mg/mL (1000x)	ThermoFisher Scientific	15750037
Amphotericin B 250 µg/mL (100x)	ThermoFisher Scientific	15290018
Fetal bovine serum (FBS)		
Ticarcillin disodium salt	Sigma-Aldrich	T5639-1G
Potassium clavulanate	Sigma-Aldrich	33454-100MG
Sterile phosphate buffer saline (PBS) pH 7.4 w/o calcium, magnesium and phenol red		
Sterile cell culture grade water		
Sterile transportation container		
70% ethanol solution		
Disinfectant solution for biological waste disposal		
Sterile metal forceps or tweezers		
Sterile metal scissors		

Sterile flat weighing metal spatula
Sterile scalpels and blades
6-well cell culture plates
12-well cell culture plates
Sterile Petri dish, 100 mm × 20 mm

Cell-free HIV-1 viral preparation HIV-1 _{BaL}	NIH AIDS Reagent Program	510
--	--------------------------	-----

Cell-free HIV-1 viral preparation HIV-1 _{LAI.04}	NIH AIDS Reagent Program	2522
---	--------------------------	------

Lamivudine (3TC)	NIH AIDS Reagent Program	8146
------------------	--------------------------	------

Biological safety cabinet
Water-jacketed CO₂ incubator, set at 37 °C,
5% CO₂, ≥ 90% humidity
Water bath set at 37 °C
Sterile 1.5- and 2-mL screw cap tubes
Dry bath shaker with heating block for 1.5-
mL tubes, set at 37 °C, 300 rpm

Comments/Description

Gelfoam and Spongostan perform equally well in histoculture for both tonsillar and cervical tissue.

To RPMI1640 add MEM non-essential aminoacids, sodium pyruvate, gentamicin, amphotericin B and FBS 15% (v/v) to make culture medium (CM).

Resuspend in sterile cell culture grade water tircacillin disodium (3g) and potassium clavulanate (100mg) and mix to obtain 100 mL of antibiotic solution (100x). Aliquote and store at -20 °C. Avoid repeated freezing and thawing. Supplement CM with antibiotic solution to make CMT.

To use for storage and transportation of surgical specimens. PBS can be replaced with another isotonic solution with physiologic pH. Culture medium is best for overnight storage.

The virus should be propagated to generate a stock large enough to perform several experiments. Aliquote virus suspension and store at -80 °C. Avoid repeated freezing and thawing.

Resuspend in DMSO at 10 mg/ml, aliquote and store at -20 °C. Avoid repeated freezing and thawing.



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

EX-VIVO INFECTION OF HUMAN LYMPHOID AND FEMALE GENITAL MUCOSA

Author(s):

INTROINI A, VANPOUILLE C, BROADEN K, MARGOLIS L

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "Derivative Work" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:

INTROIMI ANDRJA

Department:

DEPT. OF MEDICINE SOLNA


Institution:

KAROLINSKA INSTITUTE

Article Title:

EX-VIVO INFECTION OF HUMAN LYMPHOID TISSUE AND FETAL GENITAL

Signature:



Date:

07/17/2017

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Dear JoVE Editorial Team

I would like to thank you for your positive feedback on our manuscript '*Ex vivo*-infection of human lymphoid tissue and female genital mucosa with human immunodeficiency virus 1 and histoculture' and constructive comments. We tried to address all comments in the revised version of the protocol and provided a point-by-point response below.

With many thanks

Andrea Introini, PhD

Editor's comments

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.

Done.

2. Unfortunately, there are a few sections of the manuscript that show significant overlap with previously published work. Though there may be a limited number of ways to describe a technique, please use original language throughout the manuscript. Please see the *iThenticateReport* attached to this email.

We revised some sections using original language throughout the manuscript.

3. Please ensure that the references appear as the following: [Lastname, F.I., LastName, F.I., LastName, F.I. Article Title. Source. Volume (Issue), FirstPage – LastPage, doi: DOI (YEAR).] For more than 6 authors, list only the first author then *et al.*

Done. The d.o.i. is not available for some old publications.

4. Please include volume, issue numbers, and DOIs for all references.

Done.

5. Please define all abbreviations before use.

Done.

6. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

N/A.

7. Figure 1: Please use 'mL' instead of 'ml' in this figure. For x axis symbol, please use 'Time (day)' instead of 'Days'.

Done.

8. Please use standard SI unit symbols and prefixes such as μL , mL, L, g, m, etc., and h, min, s for time units. Please use a single space between numerical values and their units.

Done.

9. Line 54: At the beginning of XX century?

The section was removed as recommended by Reviewer#3.

10. Please revise the Introduction to include all of the following:

a) A description of the context of the technique in the wider body of literature

b) Information to help readers to determine whether the method is appropriate for their application

We thank the Editor for this useful suggestion. We revised the Introduction accordingly, trying to highlight the pros and cons of our experimental system in the context of HIV-1 studies, and provided more details on the technical aspects and potential applications of the method.

11. Please combine some of the shorter Protocol steps so that individual steps contain 2-3 actions and maximum of 4 sentences per step.

Done.

12. Please ensure that all text in the protocol section is written in the imperative tense as if telling someone how to do the technique (e.g., “Do this,” “Ensure that,” etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Any text that cannot be written in the imperative tense may be added as a “Note.”

Done.

13. Please specify in the Protocol for the following: how sample is collected, prepared and measured to get the value HIV-1 p24_{gag}. If you don’t need this part filmed, just include them in the protocol without highlighting in yellow.

Line 335: We refer to a methodological paper that describes the procedure for sample processing and quantification of HIV p24_{gag} in explant culture supernatant by immunoassay.

14. Protocol: 1.5: What is the size of each piece?

Line 145: We added that information to the protocol.

15. 1.8: What temperature is the incubator set at?

Line 147: We added that information to the protocol and to the Table of Materials.

16. 2.4: How much CMT is in the Petri dish?

Line 163: We added that information to the protocol.

17. 2.5: Please avoid usage of phrases such as “could be,” “should be,” and “would be” throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a “Note.” What’s the size of each piece of tonsil?

Line 168: The size of the pieces of tonsils to cut at the beginning of dissection largely depends on the overall size of the original specimen and type of surgery, and it is not relevant for the correct execution of the following steps.

18. 2.10: What’s the temperature of the incubator?

19. 3.7: What’s temperature of the incubation?

We indicated incubation conditions on line 147. The same information was added to the Table of Materials.

20. 4.5: Please avoid usage of phrases such as “could be,” “should be,” and “would be” throughout the Protocol.

Done.

21. 4.11: What's temperature of the incubation?

We indicated incubation conditions on line 147. The same information was added to the Table of Materials.

22. 4.13: What's the composition of PBS? How much PBS is in each well?

23. 4.14: How much PBS is used for washing each time?

We added PBS formulation to the Table of Materials. We added PBS volume to use for washing explants on lines 279 and 286.

24. 5.12: Please add more details to your protocol steps. Please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.

Line 309-320: We added more information on how to collect and store culture medium and explants, also by providing some references.

25. JoVE cannot publish manuscripts containing commercial language. This includes company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. Examples of commercial language in your manuscript include Gelfoam Absorbable Collagen 358 Sponge, Pfizer, Ferrosan Medical Devices, etc.

Done. We also removed the commercial name of the mix of the antibiotic ticarcillin and clavulanate (Timentin) that is now referred to as antibiotic mix solution throughout the manuscript and in the Table of Materials. Gelfoam and Ferrosan items are still present in the Table of Materials.

26. Please revise the Discussion to explicitly cover the following in detail in 3-6 paragraphs with citations:

a) Any modifications and troubleshooting of the technique

b) Any limitations of the technique

c) The significance with respect to existing methods

d) Any future applications of the technique

We revised the Discussion to provide a better explanation of the differences in HIV-1 production between tonsil and cervical explants and related infection methods as outlined in the protocol.

We also mentioned the existence of polarized models of tissue culture and HIV-1 infection by providing some references, as requested by Reviewer#2. Finally, we highlighted the issue of variability that marks the real difference between this and other experimental systems, and provided some hints for adequate experimental design and result interpretation.

Reviewers' comments

Reviewer #1

Manuscript Summary:

The text provides a methodological outline for histocultures using surgically removed human palatine tonsil or cervix that can then be used for experimental infection with HIV-1, or any other human pathogenic microbes. The technical details are written quite logically and clearly but the overall merits of this JoVE publication will reside in the accompanying video that must appropriately guide the identification of relevant tissue surfaces. Methods for tonsil histoculture were developed more than 20 years ago in the Margolis laboratory and procedures for manipulating, infecting and analyzing randomly cut tonsil blocks are well established. The use of blocks cut from reproductive tract mucosal surfaces is less well established and the suggestion of combining ectocervix- and endocervix-derived blocks seems ill-advised given recognized differences in cellular composition and potential for pre-existing inflammation in side-by-side comparisons for these two surfaces.

We thank the Reviewer for the useful feedback. We refer to the differences existing between ectocervix and endocervix on line 228. However, we do not think that the combination of endocervical and ectocervical mucosal explants is an issue for HIV infection experiments if they are equally represented in all experimental conditions, at least in our model that is non-polarized. Being cervical specimens relatively small and subject to pathological screening, they yield a limited number of explants. Therefore, as we commented in the protocol, one may consider processing and including endocervical explants in the experiment to maximize the number of experimental conditions.

Major Concerns:

1. A recommendation should be included that virus stocks are prepared for single use to avoid freeze-thaw cycling and degradation of virus infectivity.

We thank the reviewer for pointing this out. We added this information to the protocol on lines 197 and 270, and in the Table of Materials.

Minor Concerns:

1. The layout of Table 1 is potentially confusing and some cropping of text has appeared in the pdf version.

We updated the data in Table 1 and provided a better explanation of reference values of virus inoculum and virus production in the Table caption on line 356.

2. The apparent differences in infection outcome for BAL vs LAI HIV-1 stocks in tonsil and cervix blocks should be explained. How many different cervix block preparations were studied and found to be refractory to LAI infection?

We agree with the Reviewer that this aspect deserves better explanation. In the Discussion of the revised manuscript we reported on the differences in cellular composition between tonsils and cervical mucosa, with references. We also commented on the low infection rate observed with HIV-1_{LAI.04} in our model in the context of HIV-1 transmission studies. As depicted in figure 6 of reference 17, 4 out of 27 infection experiments conducted on cervico-vaginal tissue with HIV-1_{LAI.04} resulted in productive virus replication.

3. How can differences between inocula listed in Table 1 and the Day3 data points shown in Figure 1 be reconciled?

The HIV-1 inoculum values showed in Table 1 refer to individual cervical explants infected by submersion of 16 explants in 500 µL of undiluted virus stock at the concentration of 50-70 ng/mL. The concentration values of p24_{gag} measured in culture medium of cervical tissue explants at day3 shown in Figure 1 are lower than the inoculum because explants are washed in PBS to remove the excess of virus retained by the explants, as pointed out on line 288. The amount of virus detected at day 3 thus largely depends on the washing procedure and may vary between explant preparations obtained from different donors due to several factors, including presence of endocervix, mucus production, and release of absorbed virus vs. active replication.

4. Are the values shown in Figure 1 single data points from pooled samples or do the values shown represent means of independent replicate samples?

The samples from replicate wells are pooled at collection. We specified this in the protocol on lines 311, 363 and 372.

5. The text needs careful proof reading/copy editing.

Done.

Reviewer #2**Manuscript Summary:**

This is a well written methodological manuscript from a group that has pioneered the described assays. The different steps are described in great details.

Major Concerns:

N/A

Minor Concerns:

1. I have only one minor comment regarding the histoculture assay for tonsils (lymphoid tissue) and ectoservical mucosa tissues. The authors could comment on the need (or not) for further development / application of a polarized histoculture assay in the case of mucosal tissues (presumably natural infection through those sites is more directional compared to lymph nodes)

We thank the Reviewer for this remark. In the Discussion of the revised protocol on line 400, we mentioned the existence of polarized models of culture and HIV-1 infection to study mucosal transmission, and provided some references.

Reviewer #3

Manuscript Summary:

Ex vivo histoculture of human lymphoid and mucosal tissues has led to a number of advances in our understanding of the pathogenesis of HIV infection. In this paper, Introini and coworkers provide a detailed description of protocols required to perform such experiments, including ex vivo infection with HIV-1 of explants from tonsils and mucosal tissue from the female genital tract. The manuscript is clearly written and properly referenced. Please consider the following specific comments:

Major Concerns:

1. Page 2, lines 52-70. This historical section is superfluous and should be entirely deleted. The introduction can start on line 71.

We agree with the Reviewer. We modified the Introduction accordingly.

2. Page 8, lines 346-353. This entire paragraph on biosafety issues and procedures should be moved to the beginning of the Protocol Section.

Done. The paragraph is now on line 99.

Minor Concerns:

1. Page 3, line 103. What is the precise and complete composition of the culture medium? Does using human serum instead of FBS make a difference?

The composition of culture medium is indicated in the Table of Materials. Unfortunately, we have no experience with using human serum for histocultures.

2. Page 4, line 142. « pre-warmed at 22-37°C ». This is a wide range. Which temperature is best? Also see Page 5, line 213.

We modified this throughout the manuscript. We indicated 37 °C as a reference temperature.

3. Page 5, line 203. Please explain « reverse pipetting technique ».

We explained the reverse pipetting technique on line 220.

4. Page 7, line 273. « gelatin sponge ». Do you mean collagen? Also see Page 7, line 301.

We thank the reviewer for pointing out this incongruence. In the revised protocol, we refer to the sponges as gelatin sponges throughout the manuscript. The sponges that we use for histoculture are processed from porcine skin, as indicated in the Table of Materials, to obtain gelatin as defined by the manufacturers. In fact, collagen is the main component of the sponges but they are not pure collagen preparations.

5. Table of Materials/Equipment. ThermoFisher Scientific. Please also include lamivudine (3TC) in the list.

Done.

Editorial comments

1. The Protocol should be made up almost entirely of discrete steps without large paragraphs of text between sections. Please move the large paragraphs of text to Introduction/Discussion.

Done.

2. Please do not highlight notes.

Done.

3. Please revise the text to avoid the use of any personal pronouns (e.g., "we", "you", "our" etc.) in the protocol.

We removed personal pronouns in the protocol section, some are still present in the Introduction and Discussion.

4. Protocol step 3.4: "Go to paragraph 5." Please specify paragraph 5.

Line 216. We refer to the paragraph as 'paragraph 5. Histoculture'.

5. There are two Figure 1 in the Figure Legends. Please clarify.

There are two paragraphs under 'Figures and Figure legends': one refers to Table 1, the other to Figure 1.

6. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

Done.

7. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

Figure 1 is an original figure that has not been published before.